SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1521 6926 "

Sökning: L773:1521 6926

  • Resultat 1-10 av 15
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bremme, KA (författare)
  • Haemostatic changes in pregnancy
  • 2003
  • Ingår i: Best practice & research. Clinical haematology. - 1521-6926. ; 16:2, s. 153-168
  • Tidskriftsartikel (refereegranskat)
  •  
2.
  •  
3.
  •  
4.
  • Birgegard, Gunnar (författare)
  • Does anything work for anaemia in myelofibrosis?
  • 2014
  • Ingår i: Baillière's Best Practice & Research. - : Elsevier BV. - 1521-6926 .- 1532-1924. ; 27:2, s. 175-185
  • Tidskriftsartikel (refereegranskat)abstract
    • Anaemia is a common finding at diagnosis in myelofibrosis, and becomes a symptomatic problem in most patients with time. There are several treatment options for specific anaemia treatment, none of which has been tested in large, randomized, controlled trials. However, as myelofibrosis is not a disease with spontaneous remissions, even non-randomized trials carry weight In this survey, the existing evidence will be analysed, both for the commonly used treatments like erythropoiesis-stimulating agents, androgens and thalidomide and for the new drugs in the area, and conclusions will be drawn concerning standard clinical anaemia treatment in myelofibrosis, which according to evidence from studies has a 40-50% chance of response in patients with not too advanced disease. (C) 2014 Elsevier Ltd. All rights reserved.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Maclachlan, Kylee, et al. (författare)
  • Second malignancies in multiple myeloma; emerging patterns and future directions
  • 2020
  • Ingår i: Best Practice and Research: Clinical Haematology. - : Elsevier BV. - 1521-6926. ; 33:1
  • Forskningsöversikt (refereegranskat)abstract
    • The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 15

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy